路博迈中国医疗健康股票发起A（020142）成立日期2023年12月26日，最新规模1452.16万。今年以来收 益44.16%，同类排名391/4222；近一年收益58.26%，同类排名1448/3798；成立以来收益15.83%。 路博迈中国医疗健康股票发起A（020142）基金经理为李涛。 截至发稿，李涛累计任职时间1年261天，现任基金资产总规模2924.58万元，任职期间最佳基金回报 17%， 任职期间最差基金回报15.79%。 责任编辑：小浪快报 9月11日，百普赛斯跌5.15%，截至发稿，报57.67元/股，成交5075.29万元，换手率0.70%，总市值96.80 亿元。 资料显示，北京百普赛斯生物科技股份有限公司位于北京市大兴区北京经济技术开发区宏达北路8号4幢 4层,5幢4层，成立日期2010年7月22日，上市日期2021年10月18日，公司主营业务涉及提供重组蛋白等 关键生物试剂产品及技术服务。主营业务收入构成为：重组蛋白82.27%，抗体及其他试剂12.88%，技 术服务3.04%，其他(补充)1.80%。 从基金十大重仓股角度 数据显示，中国路博迈基金旗下1只基金重仓百普赛斯。路博迈 ...

Group 1 - The core point of the news is the decline in the stock price of Beijing Baipusi Biotechnology Co., Ltd., which fell by 5.13% to 57.30 CNY per share, with a total market capitalization of 9.618 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] - The trading volume for the stock was 113 million CNY, with a turnover rate of 1.53% [1] Group 2 - According to data, a fund under Bank of China Securities holds a significant position in Baipusi, with the Bank of China Health Industry Mixed Fund (002938) owning 99,000 shares, accounting for 4.48% of the fund's net value, making it the seventh-largest holding [2] - The fund has a total scale of 158 million CNY and has achieved a year-to-date return of 63.37%, ranking 206 out of 8178 in its category [2] - The fund manager, Li Mingwei, has been in charge for 2 years and 197 days, with the best and worst fund returns during his tenure both being 9.92% [3]

Group 1 - The core point of the news is that Beijing Baipusi Biotechnology Co., Ltd. experienced a stock decline of 5.21%, with a current share price of 53.35 yuan and a total market capitalization of 8.955 billion yuan [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing recombinant proteins and key biological reagent products and technical services [1] - The revenue composition of the company includes 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other supplementary sources [1] Group 2 - From the perspective of major fund holdings, Guotai Fund has a significant position in Baipusi, with its Guotai Quantitative Income Flexible Allocation Mixed A fund holding 7,700 shares, accounting for 1.25% of the fund's net value [2] - The fund has reported a year-to-date return of 27.05% and a one-year return of 58.29%, ranking 2282 out of 8191 and 1731 out of 7967 respectively in its category [2] - The fund manager, Liang Xing, has a tenure of 9 years and 84 days, with the fund's total asset scale at 24.955 billion yuan, achieving a best return of 189.2% during his tenure [2]

Group 1 - The core point of the news is the decline in the stock price of Beijing Baipusi Biotechnology Co., Ltd., which fell by 5.21% to 53.35 CNY per share, with a total market capitalization of 8.955 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] - The trading volume for the stock was 115 million CNY, with a turnover rate of 1.65% [1] Group 2 - According to data, a fund under Bank of China Securities holds a significant position in Baipusi, with 99,000 shares, accounting for 4.48% of the fund's net value, making it the seventh-largest holding [2] - The fund, named Bank of China Securities Health Industry Mixed Fund (002938), has a total scale of 158 million CNY and has achieved a return of 58.4% this year, ranking 284 out of 8191 in its category [2] - The fund manager, Li Mingwei, has been in position for 2 years and 189 days, with the best and worst fund returns during his tenure both recorded at 6.58% [3]